Floor 9-10, Building B3, Tianfu Life Science Park
No.88 South Keyuan Road, High-Tech Zone
25 articles with Hitgen Ltd
HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences
HitGen Inc. announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.
HitGen Announces Achievement of Milestone from DEL Discovery Alliance with Merck & Co., Inc., Kenilworth, NJ., USA
HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with Merck & Co. Inc., Kenilworth NJ, USA, known as MSD outside the United States and Canada. The milestone was for the identification of candidates meeting pre-defined criteria, representing the 3rd discovery program between the two companies for which HitGen has achieved this milestone.
HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs.
HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest.
HitGen Ltd. and Sun Pharma Advanced Research Company Ltd. today announced a research collaboration to identify novel small molecule leads for targets of interest.
Program could lead to new crop protection solutions for farmers worldwide
HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest.
HitGen will receive upfront payments, and be eligible for milestone payments.
HitGen Launching Initiative to Discover New Medicines to Combat Tuberculosis and MalariaGrant Funding provided by the Bill & Melinda Gates Foundation to Use HitGen’s DNA-Encoded Library Technology
HitGen Ltd. announced today a three-year grant from the Bill & Melinda Gates Foundation.
HitGen Extends and Expands Research Collaboration and License Agreement With MSD To Build and Screen Novel DNA-Encoded Libraries
Hitgen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development.
FORMA expands external discovery research footprint with dedicated unit at HitGen
HITGEN and Boehringer Ingelheim Enter DNA-Encoded Library Based Drug Discovery Research Collaboration
HitGen will receive upfront payments, and be eligible for milestone payments from Boehringer Ingelheim. Specific financial details were not disclosed.
HitGen Announces Drug Discovery Collaboration With The Scripps Research Institute And The California Institute For Biomedical Research (Calibr)
HitGen And Pfizer Enter Research Collaboration And License Agreement To Build And Screen Novel DNA-Encoded Libraries